Oct 6, 2026 06:58AM
Oct 6, 2026 05:14AM
Oct 5, 2026 08:01AM
Oct 5, 2026 08:00AM
Sep 28, 2026 07:04AM
Sep 15, 2026 04:33AM
Sep 14, 2026 04:00PM Benitec Biopharma posts wider loss as BB-301 trial advances
Sep 14, 2026 04:00PM
May 14, 2026 08:01AM
May 14, 2026 08:00AM
May 12, 2026 08:22AM
Apr 28, 2026 07:00AM
Apr 28, 2026 07:00AM
Apr 27, 2026 07:05AM Seaport Therapeutics appoints Dr. Sharon Mates to board of directors
Apr 27, 2026 07:05AM
Apr 27, 2026 07:00AM
Apr 27, 2026 07:00AM
Mar 10, 2026 07:00AM
Mar 9, 2026 12:44PM
Mar 9, 2026 07:01AM
Mar 9, 2026 07:00AM Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinic
Feb 23, 2026 07:00AM
Feb 23, 2026 07:00AM
Feb 12, 2026 08:30AM
Jan 13, 2026 04:09AM
Jan 12, 2026 09:17AM
Jan 11, 2026 08:00AM
Jan 11, 2026 08:00AM Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
Nov 18, 2025 04:18AM
Nov 14, 2025 05:00PM
Nov 4, 2025 04:58AM
Nov 3, 2025 07:10AM
Nov 3, 2025 07:10AM
Nov 3, 2025 07:02AM
Nov 3, 2025 07:00AM Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
Sep 22, 2025 04:05PM
Jul 9, 2025 08:02AM
Jul 9, 2025 08:00AM
May 14, 2025 07:00AM
Apr 10, 2025 04:04AM
Mar 19, 2025 07:00AM
Mar 19, 2025 07:00AM Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scient
Feb 14, 2025 08:10AM
Feb 14, 2025 08:01AM
Feb 14, 2025 08:00AM
Nov 14, 2024 04:30PM
Oct 14, 2024 06:00AM
Oct 12, 2024 06:30AM
Sep 26, 2024 04:30PM Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
Sep 18, 2024 08:00AM

334,287 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All